TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03345485
Drug: Tinostamustine 60mg/m2 over 30min
DrugBank: Tinostamustine (DB15147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study: NCT03345485
Drug: Tinostamustine 80mg/m2 over 30min
DrugBank: Tinostamustine (DB15147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study: NCT03345485
Drug: Tinostamustine 60mg/m2 over 60min
DrugBank: Tinostamustine (DB15147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study: NCT03345485
Drug: Tinostamustine 80mg/m2 over 60min
DrugBank: Tinostamustine (DB15147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study: NCT03345485
Drug: Tinostamustine 100mg/m2 over 60min
DrugBank: Tinostamustine (DB15147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study: NCT03345485
Drug: Tinostamustine 80mg/m2 over 80min
DrugBank: Tinostamustine (DB15147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 80 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study: NCT01906944
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
Study: NCT01906944
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone is a long-acting synthetic corticosteroid.
Study: NCT04497883
Drug: Maribavir (400 mg)
Normalized name: maribavir
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.
Study: NCT04497883
Drug: Maribavir (200 mg)
Normalized name: maribavir
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Japanese descent group participants will receive 200 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
Study: NCT04497883
Drug: Maribavir (800 mg)
Normalized name: maribavir
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Japanese descent group participants will receive 800 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
Study: NCT02660840
Drug: 0.5 mg Flupentixol film-coated tablet (test treatment)
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study: NCT02660840
Drug: 1 mg Flupentixol film-coated tablet (test treatment)
Normalized name: flupenthixol 1 MG
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study: NCT02660840
Drug: 5 mg Flupentixol film-coated tablet (test treatment)
Normalized name: flupenthixol 5 MG
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study: NCT02660840
Drug: 0.5 mg Flupentixol coated tablet (reference treatment)
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study: NCT02660840
Drug: 1 mg Flupentixol coated tablet (reference treatment)
Normalized name: flupenthixol 1 MG
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study: NCT02660840
Drug: 5 mg Flupentixol coated tablet (reference treatment)
Normalized name: flupenthixol 5 MG
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study: NCT03373227
Drug: Envarsus
Normalized name: Envarsus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take once daily Envarsus
Study: NCT00870714
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
Study: NCT00870714
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
Study: NCT00514852
Drug: Carboxymethylcellulose and Glycerin based artificial tear
Normalized name: carboxymethylcellulose / glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 drops into each eye as needed but at least twice daily
Study: NCT00514852
Drug: Carboxymethylcellulose
Normalized name: Carboxymethylcellulose
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 drops into each eye as needed but at least twice daily
Study: NCT03750916
Drug: Anlotinib Hydrochloride plus Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
Study: NCT01610284
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
Study: NCT00740610
Drug: GS-9450
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
Study: NCT04554056
Drug: MW05
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein injection
Study: NCT00802815
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 milligrams subcutaneously every week
Study: NCT00484744
Drug: Avicel (placebo)
Normalized name: Evicel
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01426542
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.
Study: NCT02816567
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02816567
Drug: NMBA - cisatracurium
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01246817
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
Study: NCT02395601
Drug: CPI-1205
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule inhibitor of the enzyme EZH2
Study: NCT03317327
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a humanized antibody used in cancer immunotherapy.
Study: NCT01508923
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
Study: NCT01500434
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
Study: NCT00389402
Drug: saquinavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00389402
Drug: atazanavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02536404
Drug: Etrasimod
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01500434
Drug: Thienopyridine
Normalized name: Phenopyridine
DrugBank: Oxyquinoline (DB11145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
Study: NCT01125358
Drug: LY2140023
Normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, twice daily for up to 7 weeks of treatment
Study: NCT03112096
Drug: [18F]THK-5351
DrugBank: THK-5351 (DB19222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
Study: NCT02817477
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delivered intranasally using an atomizer
Study: NCT02817477
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delivered either as an IM injection or a slow IV bolus
Study: NCT04332835
Drug: Plasma
Normalized name: Plasma
DrugBank: Plasma protein fraction (human) (DB13968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
Study: NCT04585061
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle
Study: NCT04352621
Drug: intranasal ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg will be administered intranasally using an atomization device with a maximum dose of 40 mg followed by 6 weeks of rTMS treatment. .
Study: NCT00065429
Drug: BB-10901
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease.
Study: NCT04003103
Drug: Islatravir
Normalized name: Islatravir
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 30 mg capsules taken by mouth.
Study: NCT02784002
Drug: Ridinilazole
Normalized name: Ridinilazole
DrugBank: Ridinilazole (DB15308)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02784002
Drug: Fidaxomicin
Normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00693056
Drug: RX-10100 5mg
Normalized name: capsaicin 0.25 MG/ML / methylnicotinate 5 MG/ML [Arth-RX]
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/dose of RX-10100
Study: NCT00693056
Drug: RX-10100 15mg
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/dose of RX-10100
Study: NCT03253263
Drug: OHB-607
Normalized name: OHB
DrugBank: Salicylamide (DB08797)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive intravenous infusion of OHB-607 from birth up to PMA 29 weeks + 6 days.
Study: NCT00003544
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02724878
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02724878
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00522132
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous application
Study: NCT00348608
Drug: iodixanol
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00486642
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00486642
Drug: Pazopanib Hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02007512
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.
Study: NCT02007512
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.
Study: NCT00502203
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses
Study: NCT00502203
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m\^2 By Vein Over 3 Hours Every 21 Days for 6 Courses
Study: NCT02007512
Drug: Placebo (for enzalutamide)
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
Study: NCT02007512
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
Study: NCT00578760
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 325mg ASA OD for the duration of the cisplatin
Study: NCT00910299
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
Study: NCT00910299
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75 mg oral daily maintenance dose up to 6 months.
Study: NCT00346424
Drug: Alfimeprase
Normalized name: Alfimeprase
DrugBank: Alfimeprase (DB04919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01251536
Drug: Dose escalation of cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly
Study: NCT01251536
Drug: Standard first line treatment with cetuximab + Folfiri
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly.
Study: NCT03601923
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib belongs to a class of anti-cancer agents known as PARP (poly ADP ribose polymerase) inhibitors. PARP is a protein in the body that repairs damage to DNA (one of the building blocks of a cell). In cells that are rapidly growing, such as cancer cells, blocking repair of DNA may be of benefit, since it will cause the cell to die.~Niraparib will be given at an initial dose of 200mg or 300 mg by mouth once daily depending on the patient's platelet count and weight at the start of the trial.
Study: NCT00700037
Drug: high-dose atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg/day
Study: NCT00700037
Drug: low-dose atorvastatin
Normalized name: ethinyl estradiol
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg/day
Study: NCT04134260
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03123406
Drug: Cinacalcet HCl
Normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
Study: NCT00993226
Drug: SABER-Bupivacaine Treatment 1a
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5.0 ml
Study: NCT00993226
Drug: Placebo SABER-Bupivacaine Treatment 1b
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5.0 ml
Study: NCT00993226
Drug: Bupivacaine HCl Treatment 1c
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 ml
Study: NCT02080273
Drug: Colgate Cavity Protection toothpaste
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
Study: NCT00993226
Drug: SABER-Bupivacaine Treatment 2a
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 ml
Study: NCT00993226
Drug: Placebo SABER-Bupivacaine Treatment 2b
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 ml
Study: NCT00993226
Drug: Bupivacaine HCl Treatment 2c
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 ml
Study: NCT01146457
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active dosage
Study: NCT01146457
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline Control
Study: NCT02496780
Drug: novolog insulin
Normalized name: insulin aspart, human Cartridge [NovoLog]
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3x daily rapid-acting insulin
Study: NCT00119678
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
Study: NCT00119678
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
Study: NCT02496780
Drug: levemir insulin
Normalized name: insulin detemir Injectable Solution [Levemir]
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: basal insulin once a day
Study: NCT03376321
Drug: Pimodivir 600 mg
Normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
Study: NCT00119678
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injectable, intravenous, 10 mg/kg, every 28 days
Study: NCT00313781
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
Study: NCT00313781
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone is administered at a dose of 5 mg twice daily.
Study: NCT03960268
Drug: Brodalumab
Normalized name: Brodalumab
DrugBank: Brodalumab (DB11776)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: interleukin 17 receptor A antagonist
Study: NCT00272662
Drug: peginesatide
Normalized name: Peginesatide
DrugBank: Peginesatide (DB08894)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00432549
Drug: Almotriptan
Normalized name: Almotriptan
DrugBank: Almotriptan (DB00918)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00432549
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03151707
Drug: Nicotinamide Riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside 2g/day for a 2 week duration
Study: NCT00514501
Drug: Iodofiltic acid I 123
Normalized name: Iodofiltic acid I 123
DrugBank: Iodofiltic acid I-123 (DB05683)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00240786
Drug: acetaminophen extended release
Normalized name: acetaminophen Extended Release Oral Tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03148691
Drug: A-101
Normalized name: YA-101
DrugBank: P-BCMA-101 (DB17371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Solution
Study: NCT00453414
Drug: Iloprost Inhalation Solution (Ventavis)
Normalized name: iloprost Inhalation Solution
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03083639
Drug: Esomeprazole Capsule
Normalized name: esomeprazole Oral Capsule
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole Capsule